(Q41764055)

English

Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities

scientific article published on 28 August 2013

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities (English)

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

P Vyas

4

0 references

author name string

M Dennis

1

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

D Culligan

2

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

D Karamitros

3

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

P Johnson

5

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

N H Russell

6

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

J Cavenagh

7

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

A Szubert

8

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

S Hartley

9

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

J Brown

10

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

D Bowen

11

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

publication date

28 August 2013

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

full work available at URL

http://eprints.whiterose.ac.uk/88055/

content deliverer

White Rose Research Online

0 references

Leukemia research reports

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

2

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

2

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

70-74

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndrome and acute myeloid leukemia with chromosome 5 abnormalities

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3850387

6 June 2018

Outcome of patients with acute myeloid leukemia with monosomal karyotype who undergo hematopoietic cell transplantation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3850387

6 June 2018

A phase 2 study of lenalidomide monotherapy in patients with deletion 5q acute myeloid leukemia: Southwest Oncology Group Study S0605.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3850387

6 June 2018

Dose escalation of lenalidomide in relapsed or refractory acute leukemias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3850387

6 June 2018

Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3850387

6 June 2018

Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3850387

6 June 2018

Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3850387

6 June 2018

Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3850387

18 August 2018

A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3850387

18 August 2018

Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3850387

18 August 2018

A phase 1 study of concomitant high-dose lenalidomide and 5-azacitidine induction in the treatment of AML

1 reference

https://pubmed.ncbi.nlm.nih.gov/24371786

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Lenalidomide maintenance after nonmyeloablative allogeneic stem cell transplantation in multiple myeloma is not feasible: results of the HOVON 76 Trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/24371786

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Coexistence of LMPP-like and GMP-like Leukemia Stem Cells in Acute Myeloid Leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/24371786

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.LRR.2013.07.003

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

9 October 2017

ResearchGate publication ID

0 references

2-s2.0-84887969365

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41764055&oldid=1927715098"